205 related articles for article (PubMed ID: 36952115)
21. Moderate versus extreme hypofractionated radiotherapy: a toxicity comparative analysis in low- and favorable intermediate-risk prostate cancer patients.
Nicosia L; Mazzola R; Rigo M; Figlia V; Giaj-Levra N; Napoli G; Ricchetti F; Corradini S; Ruggieri R; Alongi F
J Cancer Res Clin Oncol; 2019 Oct; 145(10):2547-2554. PubMed ID: 31324979
[TBL] [Abstract][Full Text] [Related]
22. High-Dose Robotic Stereotactic Body Radiotherapy in the Treatment of Patients With Prostate Cancer: Preliminary Results in 26 Patients.
Pontoriero A; Iatì G; Mondello S; Midili F; Siragusa C; Brogna A; Ielo I; Anastasi G; Magno C; Pergolizzi S; De Renzis C
Technol Cancer Res Treat; 2016 Feb; 15(1):179-85. PubMed ID: 25586517
[TBL] [Abstract][Full Text] [Related]
23. SHARP hypofractionated stereotactic radiotherapy is well tolerated in prostate cancer : Toxicity and quality of life assessment.
Rucinska M; Kieszkowska-Grudny A; Nawrocki S
Strahlenther Onkol; 2016 Jul; 192(7):449-57. PubMed ID: 27221312
[TBL] [Abstract][Full Text] [Related]
24. Acute and late complications after radiotherapy for prostate cancer: results of a multicenter randomized trial comparing 68 Gy to 78 Gy.
Peeters ST; Heemsbergen WD; van Putten WL; Slot A; Tabak H; Mens JW; Lebesque JV; Koper PC
Int J Radiat Oncol Biol Phys; 2005 Mar; 61(4):1019-34. PubMed ID: 15752881
[TBL] [Abstract][Full Text] [Related]
25. Linac-based stereotactic body radiation therapy for low and intermediate-risk prostate cancer : Long-term results and factors predictive for outcome and toxicity.
Franzese C; Badalamenti M; Di Brina L; D'Agostino G; Franceschini D; Comito T; Clerici E; Navarria P; Reggiori G; Mancosu P; Tomatis S; Scorsetti M
Strahlenther Onkol; 2020 Jul; 196(7):608-616. PubMed ID: 32303782
[TBL] [Abstract][Full Text] [Related]
26. Acute toxicity in high-risk prostate cancer patients treated with androgen suppression and hypofractionated intensity-modulated radiotherapy.
Pervez N; Small C; MacKenzie M; Yee D; Parliament M; Ghosh S; Mihai A; Amanie J; Murtha A; Field C; Murray D; Fallone G; Pearcey R
Int J Radiat Oncol Biol Phys; 2010 Jan; 76(1):57-64. PubMed ID: 19395192
[TBL] [Abstract][Full Text] [Related]
27. Safety and Efficacy of Virtual Prostatectomy With Single-Dose Radiotherapy in Patients With Intermediate-Risk Prostate Cancer: Results From the PROSINT Phase 2 Randomized Clinical Trial.
Greco C; Pares O; Pimentel N; Louro V; Santiago I; Vieira S; Stroom J; Mateus D; Soares A; Marques J; Freitas E; Coelho G; Seixas M; Lopez-Beltran A; Fuks Z
JAMA Oncol; 2021 May; 7(5):700-708. PubMed ID: 33704378
[TBL] [Abstract][Full Text] [Related]
28. Phase I/IIa trial of androgen deprivation therapy, external beam radiotherapy, and stereotactic body radiotherapy boost for high-risk prostate cancer (ADEBAR).
Kim YJ; Ahn H; Kim CS; Kim YS
Radiat Oncol; 2020 Oct; 15(1):234. PubMed ID: 33032643
[TBL] [Abstract][Full Text] [Related]
29. Stereotactic body radiotherapy (SIB-VMAT technique) to dominant intraprostatic lesion (DIL) for localized prostate cancer: a dose-escalation trial (DESTROY-4).
Deodato F; Ferro M; Bonome P; Pezzulla D; Romano C; Buwenge M; Cilla S; Morganti AG; Macchia G
Strahlenther Onkol; 2024 Mar; 200(3):239-249. PubMed ID: 38180492
[TBL] [Abstract][Full Text] [Related]
30. Hypofractionated Radiation Therapy to the Prostate Bed With Intensity-Modulated Radiation Therapy (IMRT): A Phase 2 Trial.
Leite ETT; Ramos CCA; Ribeiro VAB; Salvajoli BP; Nahas WC; Salvajoli JV; Ynoe Moraes F
Int J Radiat Oncol Biol Phys; 2021 Apr; 109(5):1263-1270. PubMed ID: 33346091
[TBL] [Abstract][Full Text] [Related]
31. Moderately Hypofractionated Helical Tomotherapy for Prostate Cancer: Ten-year Experience of a Mono-institutional Series of 415 Patients.
Cozzi S; Ruggieri MP; Alì E; Ghersi SF; Vigo F; Augugliaro M; Giaccherini L; Iori F; Najafi M; Bardoscia L; Botti A; Trojani V; Ciammella P; Iotti C
In Vivo; 2023; 37(2):777-785. PubMed ID: 36881094
[TBL] [Abstract][Full Text] [Related]
32. Toxicity and Patient-Reported Quality-of-Life Outcomes After Prostate Stereotactic Body Radiation Therapy With Focal Boost to Magnetic Resonance Imaging-Identified Prostate Cancer Lesions: Results of a Phase 2 Trial.
Morris BA; Holmes EE; Anger NJ; Cooley G; Schuster JM; Hurst N; Baschnagel AM; Bassetti MF; Blitzer GC; Chappell RJ; Bayliss RA; Morris ZS; Ritter MA; Floberg JM
Int J Radiat Oncol Biol Phys; 2023 Nov; 117(3):613-623. PubMed ID: 37179035
[TBL] [Abstract][Full Text] [Related]
33. Moderately hypofractionated salvage radiotherapy in patients with biochemical recurrence of prostate cancer after prostatectomy: long-term results and comparative analysis of two schedules.
Matrone F; Donofrio A; Fanetti G; Revelant A; Polesel J; Chiovati P; Bortolus R
Neoplasma; 2022 Dec; 69(6):1425-1436. PubMed ID: 36305692
[TBL] [Abstract][Full Text] [Related]
34. Stereotactic body radiotherapy with a focal boost to the MRI-visible tumor as monotherapy for low- and intermediate-risk prostate cancer: early results.
Aluwini S; van Rooij P; Hoogeman M; Kirkels W; Kolkman-Deurloo IK; Bangma C
Radiat Oncol; 2013 Apr; 8():84. PubMed ID: 23570391
[TBL] [Abstract][Full Text] [Related]
35. Retreatment for Local Recurrence of Prostatic Carcinoma After Prior Therapeutic Irradiation: Efficacy and Toxicity of HDR-Like SBRT.
Fuller D; Wurzer J; Shirazi R; Bridge S; Law J; Crabtree T; Mardirossian G
Int J Radiat Oncol Biol Phys; 2020 Feb; 106(2):291-299. PubMed ID: 31629838
[TBL] [Abstract][Full Text] [Related]
36. A randomized phase II trial of MR-guided prostate stereotactic body radiotherapy administered in 5 or 2 fractions for localized prostate cancer (FORT).
Wolfe S; Diven MA; Marciscano AE; Zhou XK; Kishan AU; Steinberg ML; Miccio JA; Camilleri P; Nagar H
BMC Cancer; 2023 Sep; 23(1):923. PubMed ID: 37777738
[TBL] [Abstract][Full Text] [Related]
37. Efficacy, toxicity, and quality-of-life outcomes of ultrahypofractionated radiotherapy in patients with localized prostate cancer: A single-arm phase 2 trial from Asia.
Tan JSH; Teh JYH; Tan LLY; Tan SXF; Li YQ; Tan TWK; Wang MLC; Kanesvaran R; Ong EHW; Tay KJ; Lee LS; Tuan JKL; Tan DYH; Chua MLK
Asia Pac J Clin Oncol; 2022 Oct; 18(5):e346-e355. PubMed ID: 34908240
[TBL] [Abstract][Full Text] [Related]
38. First Australian experience of treating localised prostate cancer patients with CyberKnife stereotactic radiotherapy: early PSA response, acute toxicity and quality of life.
Dixit A; Tang C; Bydder S; Kedda MA; Vosikova E; Bharat C; Gill S
J Med Radiat Sci; 2017 Sep; 64(3):180-187. PubMed ID: 28271639
[TBL] [Abstract][Full Text] [Related]
39. Treatment outcomes of postoperative ultra-hypofractionated stereotactic body radiotherapy in prostate cancer.
Ozyigit G; Onal C; Beduk Esen CS; Tilki B; Hurmuz P
Urol Oncol; 2023 May; 41(5):252.e1-252.e8. PubMed ID: 36631368
[TBL] [Abstract][Full Text] [Related]
40. Magnetic resonance imaging-guided stereotactic body radiotherapy for prostate cancer (mirage): a phase iii randomized trial.
Ma TM; Lamb JM; Casado M; Wang X; Basehart TV; Yang Y; Low D; Sheng K; Agazaryan N; Nickols NG; Cao M; Steinberg ML; Kishan AU
BMC Cancer; 2021 May; 21(1):538. PubMed ID: 33975579
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]